Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AC
Achieve Life Sciences, Inc.
ACHV
Mkt Cap
$657.4M
Volume
1.83M
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AC
ACHV
AC
Achieve Life Sciences, Inc.
ACHV
News
·
Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week
Mkt Cap
$718.6M
Volume
1.83M
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Insider
Filings
Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week
Achieve Life Sciences will host one-on-one meetings during the J.P. Morgan Healthcare Conference in January 2026, discussing its late-stage cytisinicline program for smoking and vaping cessation, with a pending FDA New Drug Application review scheduled for June 2026.
Benzinga · Dec 17, 2025
Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters’ Option to Purchase Additional Securities
Achieve Life Sciences completed a public offering of 15 million shares and accompanying warrants, raising $45 million to fund the development of cytisinicline, a potential treatment for nicotine dependence and smoking cessation.
GlobeNewswire Inc. · Jun 30, 2025
Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering
Achieve Life Sciences announced a public offering of 15 million shares and accompanying warrants at $3.00 per share, expecting to raise approximately $45 million to fund the development of cytisinicline, a potential treatment for nicotine dependence.
GlobeNewswire Inc. · Jun 27, 2025
Achieve Life Sciences Announces Proposed Underwritten Public Offering
Achieve Life Sciences plans a public offering to raise funds for advancing cytisinicline, a potential treatment for nicotine dependence and smoking cessation, after submitting a New Drug Application to the FDA in June 2025.
Benzinga · Jun 26, 2025
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program
Achieve Life Sciences reported financial results for Q4 and full-year 2024, highlighting key milestones in the cytisinicline development program, including completion of enrollment in the ORCA-OL trial and positive DSMC reviews. The company reiterated plans to submit the cytisinicline NDA by the end of Q2 2025.
GlobeNewswire Inc. · Mar 11, 2025
Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline
Achieve Life Sciences has promoted Jaime Xinos to Chief Commercial Officer to oversee the commercial operations and strategic preparations for the anticipated U.S. launch of cytisinicline, a treatment for nicotine dependence.
GlobeNewswire Inc. · Oct 16, 2024
Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting
SEATTLE and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced data from the Phase 2 ORCA-V1 vaping cessation trial will be presented today, Friday, May 17, 2024, at the Society of General Internal Medicine (SGIM) Annual Meeting being held in Boston, MA.
GlobeNewswire Inc. · May 17, 2024
Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update
Company to host conference call at 4:30 PM EDT today, Thursday, May 9, 2024 Company to host conference call at 4:30 PM EDT today, Thursday, May 9, 2024
GlobeNewswire Inc. · May 9, 2024
Rare Stock Picks In April 2024 - From 28 Discerning Analysts
The following new investment ideas were made by analysts who have NO OTHER Buy/Strong Buy recommendations in the past 3 months. Check out the picks for April 2024.
Seeking Alpha · May 7, 2024
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine
Phase 2 ORCA-V1 trial showed treatment with cytisinicline more than doubled odds of quitting e-cigarettes compared with placebo
GlobeNewswire Inc. · May 6, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
AC
ACHV
Achieve Life Sciences, Inc.
Buy
Sell
Market
Limit
Soon
ACHV
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any ACHV yet.
Related Tickers
Earnings